Cancer experts hope several promising drugs will follow the success of Genentech's Avastin and Schering-Plough Corp.'s Temodar and reduce brain cancer deaths. An experimental vaccine bought by Pfizer from Avant Immunotherapeutics allowed early clinical trial patients to live twice longer than expected. A vaccine candidate in Northwest Biotherapeutics' pipeline also extended survival to at least three years among some of the patients in an early trial.

Full Story:

Related Summaries